Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure

Shin Kashimura
ORCID logo ,
Nobuhiro Ikemura
ORCID logo ,
Shun Kohsaka
* ORCID logo ,
Yoshinori Katsumata
,
Takehiro Kimura
,
Daisuke Shinmura
,
Kotaro Fukumoto
,
Koji Negishi
,
Ikuko Ueda
,
Seiji Takatsuki
,
Masaki Ieda
Version 1 : Received: 19 December 2023 / Approved: 20 December 2023 / Online: 20 December 2023 (10:56:19 CET)

A peer-reviewed article of this Preprint also exists.

Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med. 2024, 13, 407. Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med. 2024, 13, 407.

Abstract

Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g. documented history of HF, left ventricular ejection fraction ≤40%, or BNP levels ≥100 pg/mL). Participants, aged 61±10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: Lower baseline BNP correlated with reduced AFEQT scores. Post-CA, all groups showed significant AFEQT score improvements. Lower BNP group displayed notable enhancements (18.2±1.2, 15.0±1.1, 12.6±1.2, 13.6±1.2, p<0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/ml) exhibited significant QOL improvements. Comparing PAF and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusion: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvement.

Keywords

atrial fibrillation; brain natriuretic peptide; catheter ablation; non–heart failure; quality of life

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.